Lacosamide

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instance_of gptkb:Antihero
gptkbp:approves gptkb:FDA
gptkbp:atccode N03 AX18
gptkbp:available_on gptkb:Software_Solutions
gptkb:tablet
injection
gptkbp:brand Vimpat
gptkbp:casnumber 175481-36-4
gptkbp:category gptkb:C
gptkbp:chemical_formula C13 H18 N2 O3
gptkbp:class sodium channel modulator
gptkbp:clinical_trial Phase III
gptkbp:clinical_use neuropathic pain
gptkbp:contraindication hypersensitivity to lacosamide
gptkbp:developed_by gptkb:UCB_Pharma
gptkbp:effective_date gptkb:2008
gptkbp:excretion renal
gptkbp:formulation oral solution
extended-release tablet
immediate-release tablet
https://www.w3.org/2000/01/rdf-schema#label Lacosamide
gptkbp:indication partial-onset seizures
gptkbp:interacts_with CYP450 inducers
CYP450 inhibitors
gptkbp:knockouts highly protein-bound
gptkbp:lifespan 13 hours
gptkbp:marketed_as gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkbp:mechanism_of_action enhances slow inactivation of voltage-gated sodium channels
gptkbp:metabolism primarily hepatic
gptkbp:pharmacokinetics linear pharmacokinetics
gptkbp:provides_guidance_on gptkb:Epilepsy_Foundation
gptkb:American_Academy_of_Neurology
gptkbp:research improves quality of life
effective for refractory epilepsy
potential for use in bipolar disorder
reduces seizure frequency
well tolerated in elderly patients
gptkbp:research_areas gptkb:epilepsy
neuropathic pain
gptkbp:route_of_administration oral
intravenous
gptkbp:safety_features generally well tolerated
gptkbp:side_effect dizziness
fatigue
headache
nausea
euphoria
arrhythmia
tremor
cognitive dysfunction
visual disturbances
gptkbp:used_for treatment of epilepsy
gptkbp:bfsParent gptkb:Eisai
gptkbp:bfsLayer 5